Abstract
Summary
The global biochips market size reached US$ 14.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 35.4 Billion by 2029, exhibiting a growth rate (CAGR) of 15.94% during 2024-2029. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Biochips refer to a miniaturized medical device that includes a wide collection of microarrays for performing multiple biochemical reactions simultaneously. They contain numerous biosensors that enable the screening of several biological analytes such as enzymes, proteins, DNA, biological molecules, antibodies, etc. Biochips are primarily used in drug discovery, in-vitro diagnostics, gene expression profiling, single nucleotide polymorphism genotyping, agricultural biotechnology, etc. As a result, they are widely adopted across various pharmaceutical and biotechnology companies, research and academic laboratories, and healthcare facilities.
The increasing prevalence of chronic disorders along with the rising geriatric population is currently driving the demand for biochips in the medical sector. In recent times, the growing incidences of cancer have also augmented the use of biochips for the early detection of cancerous cells in the body. In line with this, biochips are increasingly being adopted for developing targeted and personalized medicines for cancer treatment. Additionally, the growing consumer health concerns towards several viral infections and immunological disorders are also propelling the demand for biochips in new drug discovery and development activities. For instance, with the outbreak of the COVID-19 pandemic, several biotechnology and pharma companies are focusing on developing novel biochips for detecting the infection in the body. Moreover, rising advancements in microfluid technology have led to the introduction of specifically engineered biochips for various laboratory procedures. Furthermore, numerous R&D activities in the biotechnology sector have also led to the emergence of digital microfluidic biochips. The changing consumer inclination towards minimally invasive surgeries coupled with rising upgradations in nanotechnology are further driving the demand for biochips. Apart from this, the growing investments in the healthcare sector pertaining to cancer genomics, human proteome, and DNA-analysis are further anticipated to catalyze the global biochips market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global biochips market report, along with forecasts at the global, regional and country level from 2024-2029. Our report has categorized the market based on product type, fabrication technique, analysis method, application and end user.
Breakup by Product Type:
DNA Chip
Protein Chip
Lab-On-a-Chip
Enzyme Chip
Breakup by Fabrication Technique:
Microarray
Microfluidic
Breakup by Analysis Method:
Electrophoresis
Luminescence
Mass Spectrometry
Electrical Signals
Magnetism
Breakup by Application:
Molecular Analysis
Hybridization
Protein
Immunological
Biomolecules
Biomarker
Others
Diagnosis
Gene Diagnosis
Oncology
Inflammatory
Others
Non-Biological Usage
Breakup by End User:
Pharmaceutical and Biotechnology Companies
Hospitals and Diagnostics Centers
Academic & Research Institutes
Others
Breakup by Region:
North America
United States
Canada
Europe
Germany
France
United Kingdom
Spain
Russia
Italy
Others
Asia Pacific
China
Japan
India
South Korea
Australia
Others
Latin America
Mexico
Brazil
Argentina
Others
Middle East and Africa
Turkey
Saudi Arabia
United Arab Emirates
Others
Competitive Landscape:
The competitive landscape of the industry has also been examined with some of the key players being Agilent Technologies, Inc., bioMérieux SA, Bio-RAD Laboratories, Inc., CapitalBio Corporation, Dynamic Biosensors GmbH, EMD Millipore Corporation, Fluidigm Corporation, Illumina, Inc., Perkinelmer, Inc., and Thermo Fisher Scientific Inc.
Key Questions Answered in This Report:
How has the global biochips market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global biochips market?
What are the key regional markets?
What is the breakup of the market based on the product type?
What is the breakup of the market based on the fabrication technique?
What is the breakup of the market based on the analysis method?
What is the breakup of the market based on the application?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the market?
What is the structure of the global biochips market and who are the key players?
What is the degree of competition in the market?
Table of Contents
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Biochips Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Product Type
6.1 DNA Chip
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Protein Chip
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Lab-On-a-Chip
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Enzyme Chip
6.4.1 Market Trends
6.4.2 Market Forecast
7 Market Breakup by Fabrication Technique
7.1 Microarray
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Microfluidic
7.2.1 Market Trends
7.2.2 Market Forecast
8 Market Breakup by Analysis Method
8.1 Electrophoresis
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Luminescence
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Mass Spectrometry
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Electrical Signals
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Magnetism
8.5.1 Market Trends
8.5.2 Market Forecast
9 Market Breakup by Application
9.1 Molecular Analysis
9.1.1 Hybridization
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
9.1.2 Protein
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
9.1.3 Immunological
- 9.1.3.1 Market Trends
- 9.1.3.2 Market Forecast
9.1.4 Biomolecules
- 9.1.4.1 Market Trends
- 9.1.4.2 Market Forecast
9.1.5 Biomarker
- 9.1.5.1 Market Trends
- 9.1.5.2 Market Forecast
9.1.6 Others
- 9.1.6.1 Market Trends
- 9.1.6.2 Market Forecast
9.2 Diagnosis
9.2.1 Gene Diagnosis
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
9.2.2 Oncology
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
9.2.3 Inflammatory
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
9.2.4 Others
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
9.3 Non-Biological Usage
9.3.1 Market Trends
9.3.2 Market Forecast
10 Market Breakup by End User
10.1 Pharmaceutical and Biotechnology Companies
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Hospitals and Diagnostics Centers
10.2.1 Market Trends
10.2.2 Market Forecast
10.3 Academic & Research Institutes
10.3.1 Market Trends
10.3.2 Market Forecast
10.4 Others
10.4.1 Market Trends
10.4.2 Market Forecast
11 Market Breakup by Region
11.1 North America
11.1.1 United States
- 11.1.1.1 Market Trends
- 11.1.1.2 Market Forecast
11.1.2 Canada
- 11.1.2.1 Market Trends
- 11.1.2.2 Market Forecast
11.2 Europe
11.2.1 Germany
- 11.2.1.1 Market Trends
- 11.2.1.2 Market Forecast
11.2.2 France
- 11.2.2.1 Market Trends
- 11.2.2.2 Market Forecast
11.2.3 United Kingdom
- 11.2.3.1 Market Trends
- 11.2.3.2 Market Forecast
11.2.4 Spain
- 11.2.4.1 Market Trends
- 11.2.4.2 Market Forecast
11.2.5 Russia
- 11.2.5.1 Market Trends
- 11.2.5.2 Market Forecast
11.2.6 Italy
- 11.2.6.1 Market Trends
- 11.2.6.2 Market Forecast
11.2.7 Others
- 11.2.7.1 Market Trends
- 11.2.7.2 Market Forecast
11.3 Asia Pacific
11.3.1 China
- 11.3.1.1 Market Trends
- 11.3.1.2 Market Forecast
11.3.2 India
- 11.3.2.1 Market Trends
- 11.3.2.2 Market Forecast
11.3.3 Japan
- 11.3.3.1 Market Trends
- 11.3.3.2 Market Forecast
11.3.4 South Korea
- 11.3.4.1 Market Trends
- 11.3.4.2 Market Forecast
11.3.5 Australia
- 11.3.5.1 Market Trends
- 11.3.5.2 Market Forecast
11.3.6 Others
- 11.3.6.1 Market Trends
- 11.3.6.2 Market Forecast
11.4 Latin America
11.4.1 Mexico
- 11.4.1.1 Market Trends
- 11.4.1.2 Market Forecast
11.4.2 Brazil
- 11.4.2.1 Market Trends
- 11.4.2.2 Market Forecast
11.4.3 Argentina
- 11.4.3.1 Market Trends
- 11.4.3.2 Market Forecast
11.4.4 Others
- 11.4.4.1 Market Trends
- 11.4.4.2 Market Forecast
11.5 Middle East and Africa
11.5.1 Turkey
- 11.5.1.1 Market Trends
- 11.5.1.2 Market Forecast
11.5.2 Saudi Arabia
- 11.5.2.1 Market Trends
- 11.5.2.2 Market Forecast
11.5.3 United Arab Emirates
- 11.5.3.1 Market Trends
- 11.5.3.2 Market Forecast
11.5.4 Others
- 11.5.4.1 Market Trends
- 11.5.4.2 Market Forecast
12 SWOT Analysis
12.1 Overview
12.2 Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats
13 Value Chain Analysis
14 Porters Five Forces Analysis
14.1 Overview
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Degree of Competition
14.5 Threat of New Entrants
14.6 Threat of Substitutes
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Agilent Technologies, Inc
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
15.3.2 bioMérieux SA
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
15.3.3 Bio-RAD Laboratories, Inc
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
15.3.4 CapitalBio Corporation
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
15.3.5 Dynamic Biosensors GmbH
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
15.3.6 EMD Millipore Corporation
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
15.3.7 Fluidigm Corporation
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
15.3.8 Illumina, Inc
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.8.4 SWOT Analysis
15.3.9 Perkinelmer, Inc
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
15.3.10 Thermo Fisher Scientific, Inc
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis